Regulation encompasses the rules, standards, and enforcement mechanisms that governments use to shape healthcare market behavior. Effective regulation corrects market failures — information asymmetry, externalities, and natural monopolies — that prevent healthcare markets from functioning efficiently on their own. Regulatory design must balance protecting patients and ensuring quality against the costs of compliance and the risk of stifling innovation.
States adopting direct tort reforms (caps on damages, collateral source reform) reduced hospital expenditures by 5-9% within 3-5 years without measurable increases in adverse outcomes. Defensive medicine — treatment intensity driven by liability fear rather than clinical need — accounted for a substantial share of cardiac treatment costs.
States that removed CON regulations did not experience significant increases in per-capita health spending compared to states retaining CON. There was little evidence that CON effectively constrained health spending or facility investment, and some evidence that CON protected incumbent providers from beneficial competition.
Countries with stringent direct price controls had lower launch prices but also fewer available products and delayed market entry of new drugs. Reference pricing (using prices in other countries as benchmarks) was associated with lower prices without the same access delays. Overly restrictive regulation reduced generic competition and pharmaceutical market entry.
Each additional patient per nurse was associated with a 7% increase in the likelihood of patient death within 30 days and a 7% increase in failure-to-rescue. Hospitals with the highest patient-to-nurse ratios (1:8) had 31% higher risk-adjusted mortality than those with the lowest ratios (1:4).
Report cards led to significant provider selection behavior ('cream-skimming'): surgeons and hospitals shifted away from sicker, higher-risk patients. On net, report cards were associated with worse health outcomes, particularly for sicker patients, and higher resource use.
Multifaceted interventions combining educational outreach, reminders, and audit-and-feedback produced the most consistent behavior change. Passive guideline dissemination alone had minimal effect. Median absolute improvement in care processes ranged from 6-10% for active implementation strategies. No single strategy was reliably superior across all settings.
Hospitals responded primarily through 'upcoding' — reclassifying patients to diagnosis codes associated with the largest reimbursement increases — garnering an estimated $330–$425 million in extra annual reimbursement. Response was strongest among for-profit hospitals. Little evidence of changes in admissions volume or clinical intensity.
Evidence for the effectiveness of external inspection and accreditation on quality outcomes was inconsistent. While accreditation promoted implementation of organizational processes and standards, direct links to improved patient outcomes were difficult to establish. The strongest effects were on process measures and organizational compliance rather than clinical outcomes.
Hospitals in less competitive (more concentrated) markets had significantly higher death rates before the reform; after patient choice was expanded, outcomes converged. Competition saved lives without raising costs.
Improved risk adjustment reduced favorable selection into MA plans by 15–20%. However, plans responded to the new formula by intensifying diagnostic coding — upcoding increased, with MA enrollees showing 6–16% higher risk scores than comparable fee-for-service beneficiaries, representing billions in excess payments.
Adding a rival hospital increased management quality by approximately 0.4 standard deviations and increased emergency AMI survival rates by 9.7%. The causal chain runs: competition → better management → better outcomes. Government-owned hospitals scored significantly lower on management than private ones.
Technologies with ICERs below 20,000 GBP per QALY were almost always recommended; those above 30,000 GBP per QALY were frequently rejected. However, NICE also systematically weighted other factors: severity of condition, availability of alternatives, and innovation. End-of-life treatments received higher effective thresholds. The implicit threshold was approximately 20,000–30,000 GBP per QALY.
Nurse-led primary care produced equivalent or better health outcomes compared to physician-led care for a wide range of conditions. Patient satisfaction was equal or higher with nurse-led care. Consultations were longer but generated similar numbers of prescriptions, investigations, and referrals. No evidence of worse outcomes for any condition studied.